No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection By Ogkologos - June 22, 2026 94 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis May 25, 2023 Cancer research in 2020: A spotlight on Manchester December 27, 2020 Scientists reveal how air pollution can cause lung cancer in people... September 10, 2022 New on NCI’s Websites for December 2022 December 27, 2022 Load more HOT NEWS Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... Cleveland Clinic Launches Breast Cancer Vaccine Trial The team tackling the serious side effects of cancer treatment in... Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing...
